Valuation: ICAD

Market Cap 106M 92.74M 86.25M 79.14M 149M 10.17B 151M 1.02B 400M 5B 396M 388M 17.29B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.95M 72.49M 66.52M 125M 8.55B 127M 861M 336M 4.2B 333M 326M 14.53B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
15.55
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap.
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
7/17/25 Issuer sale

Director

82,056 0.3092%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+15.87% 106M
-0.71%+6.72%+19.63%-0.57% 211B
-0.52%-6.05%-5.58%-25.77% 135B
+1.65%-2.29%-30.93%+4.31% 119B
+1.54%+0.50%-58.34%-15.18% 65.77B
-1.42%-3.62%+9.01%-9.60% 47.58B
+3.03%-0.17%-26.81%-31.58% 44.44B
-0.84%+5.41%+15.14%+8.50% 39.14B
-2.02%+1.54%+25.53%+30.56% 36.79B
-1.41%+3.99%+80.31%+3.20% 29.37B
Average +0.31%+0.43%+2.80%-2.03% 72.82B
Weighted average by Cap. -0.00%+0.37%-1.38%-6.02%

Financials

2023 2024
Net sales 17.32M 15.21M 14.15M 12.98M 24.39M 1.67B 24.76M 168M 65.62M 820M 65.01M 63.61M 2.83B 19.61M 17.22M 16.02M 14.7M 27.61M 1.89B 28.04M 190M 74.3M 928M 73.61M 72.02M 3.21B
Net income -4.85M -4.26M -3.96M -3.63M -6.83M -467M -6.93M -47.01M -18.37M -229M -18.2M -17.8M -793M -5.62M -4.93M -4.59M -4.21M -7.91M -541M -8.03M -54.47M -21.28M -266M -21.08M -20.63M -919M
Net Debt -21.21M -18.63M -17.32M -15.9M -29.87M -2.04B -30.33M -206M -80.37M -1B -79.62M -77.9M -3.47B -16.84M -14.79M -13.76M -12.62M -23.72M -1.62B -24.09M -163M -63.83M -797M -63.23M -61.87M -2.76B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock